Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexamethasone-cyclodextrin nanoparticle eye drops
- Development stage
- Unknown
- Lead developer
- King Saud University
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Ophthalmic, Topical
01
Overview
Dexamethasone-cyclodextrin nanoparticle eye drops are a novel topical ophthalmic formulation developed by researchers at King Saud University for the treatment of posterior segment ocular diseases, specifically diabetic macular edema (DME). This formulation utilizes cyclodextrin-based nanoparticle technology to enhance the delivery of dexamethasone, a potent synthetic glucocorticoid, to the retina. By encapsulating the drug in cyclodextrin complexes that aggregate into nanoparticles, the technology significantly increases the solubility and permeability of dexamethasone across ocular barriers while minimizing systemic absorption and associated side effects. This approach aims to provide a non-invasive, topical alternative to traditional intravitreal injections for managing retinal inflammation and vascular permeability.
- Other names
- dexamethasone - Cyclodextrin eye dropsdexamethasone NP eye dropsTopical Dexamethasone - Cyclodextrin Microparticle Eye Dropsdexamethasone-cyclodextrin nanoparticles
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on dexamethasone-cyclodextrin nanoparticle eye drops.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexamethasone-cyclodextrin nanoparticle eye drops.